基础医学与临床 ›› 2018, Vol. 38 ›› Issue (7): 1016-1019.
• 短篇综述 • 上一篇 下一篇
许洋1,张雅敏1,王建2,刘子荣1
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
摘要： CAR-T技术作为免疫治疗的一种，从最早期的第1代发展至目前的第4代，其细胞毒性和抗肿瘤免疫效应大大增强，但也暴露出相应的安全问题，其在原发性肝癌治疗的相关研究中展现出一定优势，预示着在精准个体化肝癌治疗时代，免疫治疗尤其CAR-T技术联合手术治疗、放化疗和局部治疗等综合治疗将会发挥更强有力的作用。
关键词: 原发性肝癌, 免疫治疗, CAR-T疗法, 靶点抗原
Abstract: CAR-T technology as a kind of immunotherapy, from the earlist generation of the first to the current fourth generation, its cytotoxic, anti-tumor immune effect greatly enhanced, but also challenged by safety issues. It shows a certain advantage in the therapy of hepatocellular carcinoma. It indicates that the era of precise individualized liver cancer treatment, immune therapy, especially CAR-T technology combined with surgery, radiotherapy and chemotherapy, local treatment and other comprehensive treatment will play a more powerful role.
Key words: Primary liver cancer, immune therapy, CAR-T therapy, Target antigen
许洋 张雅敏 王建 刘子荣. 嵌合抗原受体T细胞治疗原发性肝癌的研究进展[J]. 基础医学与临床, 2018, 38(7): 1016-1019.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2018/V38/I7/1016
